Disease Category Listing By Location Lymphoma, Follicular

Clinical Trial Search

Lymphoma, Follicular

Click on a link below the country name to see trial details in a specific location

ARGENTINA

BUENOS AIRES BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
CÓRDOBA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
Rosario BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Australia

FITZROY BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
KURRALTA PARK BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

AUSTRALIA

KOGARAH, New S BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
Sydney, New S BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Brazil

BARRETOS BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
PORTO ALEGRE BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
SAO PAULO BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

BRAZIL

Sao Paulo, SP BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Canada

MONTREAL, QC GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
CALGARY, AB BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
ST. JOHN'S, NL BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
HALIFAX, NS BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
MONTREAL, QC BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

CANADA

EDMONTON, Alber GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Vancouver, Briti GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Quebec, Quebe BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Czech Republic

BRNO BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

CZECH REPUBLIC

Hradec Kralove BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
PRAHA 2 BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

DENMARK

Herlev BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Ecuador

QUITO BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

ECUADOR

Guayaquil BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Finland

HELSINKI BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
TAMPERE BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
TURKU BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

France

FRANCE

Lille GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Montpellier GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Pierre Benite GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
MARSEILLE BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
Montpellier BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
Reims BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Germany

HEIDELBERG GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting

GERMANY

GREECE

ATHENS ML22236
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma Completed
PATRAS ML22236
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma Completed
THESSALONIKI ML22236
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma Completed

Hungary

BUDAPEST ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
GYULA ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
KAPOSVAR ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
SZEGED ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
SZÉKESFEHÉRVÁR ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
SZEKSZARD ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
SZOLNOK ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
TATABÁNYA ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
VESZPREM ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
ZALAEGERSZEG ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting

HUNGARY

Budapest ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
Debrecen ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
GYOR ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
MISKOLC ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
Nyíregyháza ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
PECS ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting
SZOMBATHELY ML18167
A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma Active, not recruiting

Israel

HAIFA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

ISRAEL

JERUSALEM BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
PETACH TIKVA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
RAMAT GAN BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Italy

BOLOGNA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
MILANO GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
ROMA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
BERGAMO BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
MILANO BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
PISA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
TORINO BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

ITALY

MACEDONIA, THE FORMER YU

SKOPJE ML27993
An Observational Study of First-Line Maintenance MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma Recruiting

Mexico

MEXICO CITY BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

MEXICO

Aguascalientes BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
MONTERREY BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

NETHERLANDS

AMSTERDAM GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting

NORWAY

Oslo BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Peru

LIMA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

PERU

Lima BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Poland

WROCLAW BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

POLAND

Warszawa BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Republic of Korea

SEOUL BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

RUSSIAN FEDERATION

MOSCOW BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Slovakia

BRATISLAVA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Spain

BARCELONA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

SPAIN

SALAMANCA, SALAM BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
SEVILLA, SEVIL BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Sweden

HUDDINGE BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
SUNDSVALL BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
UPPSALA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

SWEDEN

UMEA BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

Switzerland

BASEL BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

U.S.A.

WASHINGTON, DC GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
LAS VEGAS, NV GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
BUFFALO, NY GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
PORTLAND, OR GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting

United Kingdom

CAMBRIDGE BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
MANCHESTER BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting
NOTTINGHAM BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

UNITED KINGDOM

London BP22333
A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma Active, not recruiting

UNITED STATES

Los Angeles, CA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Stanford, CA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Denver, CO GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Fort Myers, FL GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Sarasota, FL GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Boston, MA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Ann Arbor, MI GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Morristown, NJ GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
New York, NY GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Cincinnati, OH GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
EUGENE, OR GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Nashville, TN GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Dallas, TX GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
San Antonio, TX GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Tyler, TX GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Fairfax, VA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Roanoke, VA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Seattle, WA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
VANCOUVER, WA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
YAKIMA, WA GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting
Madison, WI GO27834
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma Recruiting

About This Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

> For more information

Common Questions